ThermoGenesis Holdings, Inc. · OTC:THMO

ThermoGenesis — Cesca Therapeutics — Investor Presentation (May 2014)

22 slides from ThermoGenesis's investor presentation, May 2014

  1. Slide 1: Corporate Presentation May 2014

    Corporate Presentation May 2014

  2. Slide 2: Forward Looking Statement

    CescaTM Therapeutics Forward Looking Statement This presentation contains forward-looking statements. Such forward-looking statements include but are not limited to that Cesca Therapeutics Inc. will provide unmatched world- class capability and service to its clients. These statements involve risks

  3. Slide 3: Corporate Snapshot

    Cesca Therapeutics Corporate Snapshot NASDAQ Symbol KOOL Market Capitalization $57 Million Shares Outstanding 32.6 Million Options Outstanding 1.3 Million Warrants Outstanding 2.8 Million Stock Price $1.74 Average Trading Volume 0.5 Million Revenue (TTM) $17 Million Assets $14 Million Debt None Corp

  4. Slide 4: Regenerative Medicine Investor Checklist

    Cesca Therapeutics Regenerative Medicine Investor Checklist • Clinically effective? • Safe? • Large market opportunities? • Regulatory endorsement? • Cost effective delivery? • Reimbursable? 4 | Page

  5. Slide 5: Go-to-Market Success Formula

    Cesca Therapeutics Go-to-Market Success Formula CT Development Approach CT Product Attributes Autologous Cells = Naturally Safest + + Minimally Manipulated = Regulatory Fast track + + Bedside, single 60 min proc = Process Control, Low COGS + + Tested Cell formulations > 600 Trial Patients = Proven c

  6. Slide 6: Regulatory "Sweet Spot"

    Cesca Regulatory “Sweet Spot” Lower risk = speed to market 6 | Page

  7. Slide 7: An integrated regenerative medicine company

    Cesca Therapeutics An integrated regenerative medicine company Uniquely positioned to be a best in class Integrated Regenerative Medicine Company − Devices; patented platform technology − Proprietary cell formulations − Clinical Research Organization (Fortis embedded) First commercially viable autol

  8. Slide 8: Commercialization Advantage

    Cesca Therapeutics Commercialization Advantage 8 | Page

  9. Slide 9: Clinical Trial Pipeline

    Clinical Trial Pipeline Blockbuster therapy candidates $.7B 9 | Page

  10. Slide 10: Clinical Trial Pipeline Milestones

    Clinical Trial Pipeline Milestones Substantial clinical value drivers CLI Milestones Time Period FDA Pre-IDE meeting request Q1 2014 FDA IDE meeting Q2 2014 FDA IDE Pivotal Phase Approval Q4 2014 India IDE Approval Q1 2015 EU IDE Approval Q1 2015 Pivotal Enrollment Begins Q1 2015 Pivotal Phase Compl

  11. Slide 11: Clinical Trial Pipeline Milestones

    Clinical Trial Pipeline Milestones Substantial clinical value drivers AMI Milestones Time Period DCGI Phase II Approval Q1 2015 First Patient Treatment Q1 2015 Feasibility Study Complete 2016 US/EU/India approval for Pivotal 2017 WW Pivotal Phase Enrollment 2017 11 | Page

  12. Slide 12: Fortis Partnership

    Fortis Partnership CRO embedded in New Delhi facility Cesca is exclusive regenerative medicine provider to Fortis • 72 hospitals (6 countries) • 10,000 inpatient beds • 15,000 outpatients per day • Competent clinical research staff • 2x as many sites as Kaiser Physician/patient access World class cl

  13. Slide 13: Critical Limb Ischemia

    Critical Limb Ischemia Compelling clinical vascular results Trial Results Major Revascularization All patients “no option” and near term leg amputation recommended 12 Month F/U Data • Major Amputation Free Rate post SurgWerks™ Therapy = 82.4% • Reduction in VAS Pain Score from 7.8±0.97 to 0.2±0.58 •

  14. Slide 14: Acute Myocardial Infarction

    Acute Myocardial Infarction Compelling clinical cardiac results Trial Results Cardiac Tissue Repair • LVEF improvement = from 36% to 60% • Stroke volume improvement = from 39.7cc to 80cc • Scar remains 11% of total heart mass • Normal life resumed • N=1 patient (24 Mo F/U) Pilot Ph II Completed Begi

  15. Slide 15: Bone Marrow Transplant

    Bone Marrow Transplant Automating clinical major mismatch & haploidentical transplant Major ABO Clinical Results • High CD34 recoveries = 77.7% • Low hematocrit = HcT<12% • Neutrophil engraftment = Day 18 • Platelet engraftment = Day 35 • N=10 patients (40% completed) Improves Pediatric BMT (40% are

  16. Slide 16: SurgWerks

    Cesca SurgwerksTM Indication specific POC process control Step 1: Cell product - Preparing the cellular therapeutic cocktail SurgWerks POC Advantages: • “Smart” cell formulation & verification • Autologous (safe and fast) • Data validated • Structured, protocol driven • Highly consistent • Dose cont

  17. Slide 17: Cesca Cellwerks: Our Unique Development Process

    SM Cesca Cellwerks Our Unique Development Process Cell Therapy in a Box Uniquely integrated development • Chemistry, cellularity and quality • Controlled, consistent delivery • 600 patients treated across eight clinical indications 17 | Page

  18. Slide 18: Sustainable differentiation

    Cesca SurgwerksTM Sustainable differentiation Significant commercial experience, proven technical reliability • Over 20,000 patients treated @ POC with Cesca Cell Technologies • Over 600,000 cord samples processed (laboratory) • Near six-sigma disposable quality levels Clinically validated, propriet

  19. Slide 19: Management Highlights

    Management Highlights Chief Executive Officer & Director Matthew T. Plavan - Leading Cesca since 2012, effected merger with TotipotentRX in 2014, served as COO and EVP Business Development, 2008-2010, CFO from 2005. Prior experience includes McKesson/Ernst & Young. President & Director Kenneth L. Ha

  20. Slide 20: Regenerative Medicine Investor Checklist

    Cesca Therapeutics Regenerative Medicine Investor Checklist  Clinically effective  Safe  Large Market Opportunities  Regulatory approvals  Cost effective delivery  Reimbursable 20 | Page

  21. Slide 21: Market Cap Snapshot

    Cesca Therapeutics Market Cap Snapshot Cell Therapy Peer Company TCKR Market Capitalization (000’S) Aastrom Biosciences Inc. ASTM $27,000 Athersys ATHX $225,000 BioTime, Inc. BTX $202,000 Cytomedix, Inc. CMXI $69,000 Neuralstem, Inc. CUR $356,000 Cytori Therapeutics Inc. CYTX $191,000 Dendreon Corpo

  22. Slide 22: Thank you

    Thank you @

Cesca Therapeutics — Investor Presentation (May 2014) on 6ix